您的当前位置:首页 > 行业数据 > 格索雷塞疗效与安全性优于此前FDA获批的其他KRASG12C抑制剂
图片属性
图片格式:PNG 图片大小:297KB 图片尺寸:1811*735
同报告图片
 / 4
格索雷塞疗效与安全性优于此前FDA获批的其他KRASG12C抑制剂_第1页
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
格索雷塞疗效与安全性优于此前FDA获批的其他KRASG12C抑制剂_第2页
格索雷塞疗效与安全性优于此前FDA获批的其他KRASG12C抑制剂_第3页
格索雷塞疗效与安全性优于此前FDA获批的其他KRASG12C抑制剂_第4页
格索雷塞疗效与安全性优于此前FDA获批的其他KRASG12C抑制剂_第5页
所属报告: 中国生物制药(1177.HK)-港股公司研究报告:传统Pharma龙头加速创新转型拓展全球布局-250922(46页).pdf
打包全文图表

相关数据

客服
商务合作
小程序
服务号
折叠